LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals

Curr Neuropharmacol. 2016;14(2):155-64. doi: 10.2174/1570159x14666151204122017.


Neuroinflammation is an important feature in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer´s disease (AD), Parkinson´s disease (PD), frontotemporal dementia and amyotrophic lateral sclerosis. Based on current knowledge in the field, suggesting that targeting peripheral inflammation could be a promising additional treatment/prevention approach for neurodegenerative diseases, drugs and natural products with anti-inflammatory properties have been evaluated in animal models of neuroinflammation and neurodegeneration. In this review, we provide an extensive analysis of one of the most important and widely-used animal models of peripherally induced neuroinflammation and neurodegeneration - lipopolysaccharide (LPS)-treated mice, and address the data reproducibility in published research. We also summarize briefly basic features of various natural products, nutraceuticals, with known anti-inflammatory effects and present an overview of data on their therapeutic potential for reducing neuroinflammation in LPS-treated mice.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Astrocytes / metabolism
  • Brain / drug effects
  • Brain / metabolism
  • Dietary Supplements*
  • Disease Models, Animal*
  • Encephalitis / chemically induced
  • Encephalitis / etiology
  • Encephalitis / metabolism*
  • Encephalitis / prevention & control*
  • Lipopolysaccharides / administration & dosage*
  • Mice
  • Microglia / metabolism
  • Neurodegenerative Diseases / complications*
  • Reproducibility of Results


  • Anti-Inflammatory Agents
  • Lipopolysaccharides